Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer

Zhao, Eric Y., Shen, Yaoqing, Pleasance, Erin, Kasaian, Katayoon, Leelakumari, Sreeja, Jones, Martin, Bose, Pinaki, Ch'ng, Carolyn, Reisle, Caralyn, Eirew, Peter, Corbett, Richard, Mungall, Karen L., Thiessen, Nina, Ma, Yussanne, Schein, Jacqueline E., Mungall, Andrew J., Zhao, Yongjun, Moore, Richard A., Den Brok, Wendie, Wilson, Sheridan, Villa, Diego, Shenkier, Tamara, Lohrisch, Caroline, Chia, Stephen, Yip, Stephen, Gelmon, Karen, Lim, Howard, Renouf, Daniel, Sun, Sophie, Schrader, Kasmintan A., Young, Sean, Bosdet, Ian, Karsan, Aly, Laskin, Janessa, Marra, Marco A., Jones, Steven J.M. · 2017 · Clinical Cancer Research

Abstract

Purpose: Recent studies have identified mutation signatures of homologous recombination deficiency (HRD) in over 20% of breast cancers, as well as pancreatic, ovarian, and gastric cancers. There is an urgent need to understand the clinical implications of HRD signatures. Whereas BRCA1/2 mutations confer sensitivity to platinum-based chemotherapies, it is not yet clear whether mutation signatures can independently predict platinum response. Experimental Design: In this observational study, we sequenced tumor whole genomes (100× depth) and matched normals (60×) of 93 advanced-stage breast cancers (33 platinum-treated). We computed a published metric called HRDetect, independently trained to predict BRCA1/2 status, and assessed its capacity to predict outcomes on platinum-based chemotherapies. Clinical endpoints were overall survival (OS), total duration on platinum-based therapy (TDT), and radiographic evidence of clinical improvement (CI). Results: HRDetect predicted BRCA1/2 status with an area under the curve (AUC) of 0.94 and optimal threshold of 0.7. Elevated HRDetect was also significantly associated with CI on platinum-based therapy (AUC = 0.89; P = 0.006) with the same optimal threshold, even after adjusting for BRCA1/2 mutation status and treatment timing. HRDetect scores over 0.7 were associated with a 3-month extended median TDT (P = 0.0003) and 1.3-year extended median OS (P = 0.04). Conclusions: Our findings not only independently validate HRDetect, but also provide the first evidence of its association with platinum response in advanced breast cancer. We demonstrate that HRD mutation signatures may offer clinically relevant information independently of BRCA1/2 mutation status and hope this work will guide the development of clinical trials. Clin Cancer Res; 23(24); 7521–30. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1941

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 183

Metadata

Authors
Zhao, E. Y., Shen, Y., Pleasance, E., Kasaian, K., Leelakumari, S., Jones, M., Bose, P., Ch'ng, C., Reisle, C., Eirew, P., Corbett, R., Mungall, K. L., Thiessen, N., Ma, Y., Schein, J. E., Mungall, A. J., Zhao, Y., Moore, R. A., Den Brok, W., Wilson, S., Villa, D., Shenkier, T., Lohrisch, C., Chia, S., Yip, S., Gelmon, K., Lim, H., Renouf, D., Sun, S., Schrader, K. A., Young, S., Bosdet, I., Karsan, A., Laskin, J., Marra, M. A., & Jones, S. J. M.
Venue
Clinical Cancer Research
Published
2017-12-14
Volume
23
Issue
24
Pages
7521-7530
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2771217224
Cited by
183
References
7
FWCI
9.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1941
The paper
Zhao, E. Y., Shen, Y., Pleasance, E., Kasaian, K., Leelakumari, S., Jones, M., Bose, P., Ch'ng, C., Reisle, C., Eirew, P., Corbett, R., Mungall, K. L., Thiessen, N., Ma, Y., Schein, J. E., Mungall, A. J., Zhao, Y., Moore, R. A., Den Brok, W., . . . Jones, S. J. M. (2017). Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1941

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.